[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA04001125A - Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no. - Google Patents

Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no.

Info

Publication number
MXPA04001125A
MXPA04001125A MXPA04001125A MXPA04001125A MXPA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A
Authority
MX
Mexico
Prior art keywords
valence
vaccine composition
valences
adjuvant
enhanced
Prior art date
Application number
MXPA04001125A
Other languages
English (en)
Inventor
Francon Alain
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8866367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04001125(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of MXPA04001125A publication Critical patent/MXPA04001125A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se relaciona a una composicion de vacuna, que comprende dos valencias; (i) una primera valencia la cual es adyuvante-mejorada con hidroxido de aluminio e (ii) una segunda valencia la cual contiene un polisacarido de capsula bacterial que comprende uno o mas grupos O-acetilo, y en los cuales no se adsorbe con oxido de aluminio debido a la presencia de un compuesto protector el cual puede ser un fosfato, un citrato o un carbonato y el cual evita tal adsorcion. La primera valencia puede ser cualquier valencia de vacuna. En una modalidad particular, la composicion de vacuna contiene (i) la valencia de Hepatitis A, adsorbida en hidroxido de aluminio e (ii) la valencia de fiebre tifoidea formada por el polisacarido Vi de la capsula de Salmonella tyhpi.
MXPA04001125A 2001-08-08 2002-07-31 Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no. MXPA04001125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110573A FR2828406B1 (fr) 2001-08-08 2001-08-08 Composition vaccinale bivalente havi
PCT/FR2002/002770 WO2003013600A1 (fr) 2001-08-08 2002-07-31 Composition vaccinale comprenant au moins deux valances, l'une adjuvantee, l'autre pas

Publications (1)

Publication Number Publication Date
MXPA04001125A true MXPA04001125A (es) 2004-05-20

Family

ID=8866367

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001125A MXPA04001125A (es) 2001-08-08 2002-07-31 Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no.

Country Status (22)

Country Link
US (1) US7404960B2 (es)
EP (1) EP1416958B2 (es)
JP (1) JP4221291B2 (es)
KR (1) KR100881703B1 (es)
CN (1) CN1282486C (es)
AT (1) ATE357929T1 (es)
AU (1) AU2002342949B2 (es)
BR (1) BRPI0211151B8 (es)
CA (1) CA2455406C (es)
CY (1) CY1107619T1 (es)
DE (1) DE60219177T3 (es)
DK (1) DK1416958T4 (es)
ES (1) ES2284940T5 (es)
FR (1) FR2828406B1 (es)
HU (1) HU228216B1 (es)
IL (2) IL159519A0 (es)
MX (1) MXPA04001125A (es)
NZ (1) NZ530727A (es)
PL (1) PL215134B1 (es)
PT (1) PT1416958E (es)
WO (1) WO2003013600A1 (es)
ZA (1) ZA200400022B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464522C (en) 2004-04-15 2011-11-15 Eng-Hong Lee Soft gel delivery system for treating poultry
BRPI0716518B8 (pt) * 2006-09-07 2021-05-25 Glaxosmithkline Biologicals Sa vacina de ipv e uso da mesma
KR101101901B1 (ko) * 2009-01-30 2012-01-02 주식회사 리노 주방용 선반
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1285666A1 (en) * 1998-08-28 2003-02-26 SMITHKLINE BEECHAM BIOLOGICALS s.a. Salmonella typhi vaccine compositions
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions

Also Published As

Publication number Publication date
EP1416958A1 (fr) 2004-05-12
CA2455406C (en) 2012-03-13
ZA200400022B (en) 2006-05-31
NZ530727A (en) 2004-06-25
CN1541108A (zh) 2004-10-27
EP1416958B1 (fr) 2007-03-28
HUP0401182A2 (hu) 2004-09-28
PT1416958E (pt) 2007-05-31
US20040170648A1 (en) 2004-09-02
HU228216B1 (en) 2013-02-28
DE60219177D1 (de) 2007-05-10
HUP0401182A3 (en) 2004-10-28
FR2828406A1 (fr) 2003-02-14
BRPI0211151B8 (pt) 2021-05-25
FR2828406B1 (fr) 2005-06-24
WO2003013600A1 (fr) 2003-02-20
DK1416958T3 (da) 2007-07-30
DK1416958T4 (da) 2012-07-09
PL367904A1 (en) 2005-03-07
ATE357929T1 (de) 2007-04-15
CA2455406A1 (en) 2003-02-20
KR100881703B1 (ko) 2009-02-06
IL159519A (en) 2010-11-30
US7404960B2 (en) 2008-07-29
KR20040043182A (ko) 2004-05-22
PL215134B1 (pl) 2013-10-31
BR0211151A (pt) 2004-08-10
JP2005501081A (ja) 2005-01-13
JP4221291B2 (ja) 2009-02-12
ES2284940T3 (es) 2007-11-16
AU2002342949B2 (en) 2007-07-05
CY1107619T1 (el) 2013-04-18
EP1416958B2 (fr) 2012-03-14
BRPI0211151B1 (pt) 2019-07-09
CN1282486C (zh) 2006-11-01
DE60219177T3 (de) 2012-08-30
ES2284940T5 (es) 2012-07-02
DE60219177T2 (de) 2008-01-24
IL159519A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
CA2534625A1 (en) Infection prophylaxis using immune response modifier compounds
ATE322287T1 (de) Solubisierung von kapseln polysacchariden
PT777490E (pt) Enterotoxina mutante eficaz como adjuvante oral nao toxico
SE0102315D0 (sv) Compounds
AU2001278003A1 (en) Bacteriophage having multiple host range
CA2096529A1 (en) Recombinant avirulent salmonella antifertility vaccines
MXPA04001125A (es) Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no.
DE60225349D1 (de) Immunstimulierende und regulierende zusammensetzung mit bakteriellen chromosomalen dna-fragmenten und nichttoxischen lipopolysacchariden
ATE355853T1 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
TW200515917A (en) Methods and compositions for the generation of a protective immune response against SARS-COV
EP0810283A3 (en) Live attenuated RTX-procucing bacteria of the family Pasteurellaceae
BR0114403A (pt) Polipeptìdeos de "haemophilus influenzae" que podem ser usados para fins de profilaxia, diagnóstico e/ou terapia
MX9704061A (es) Bacterias productoras de rtx atenuadas vivas de la familia pasteurellaceae.
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
WO2002045738A3 (es) Composicion vacunal que contiene factor de crecimiento transformante alfa
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
Feterl et al. Supplementary materials: The epidemiology of malaria in Kutubu, Southern Highlands Province, Papua New Guinea, before and during a private sector initiative for malaria control
Howard The Host of Dreams
RU98110352A (ru) Шихта для получения водоустойчивого известкового клинкера
ITVA20020058A1 (it) Composizioni di pvc stabili al calore.
FI864769A (fi) Icke-adjuvanserad vaccin.
JP2003144089A5 (es)
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции
YU33999A (sh) Metoprolol preparat i postupak za dobijanje istog

Legal Events

Date Code Title Description
FG Grant or registration